Curbstone Financial Management Corp Acquires New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Curbstone Financial Management Corp acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 8,240 shares of the biopharmaceutical company's stock, valued at approximately $526,000.

A number of other institutional investors also recently added to or reduced their stakes in HALO. Norges Bank bought a new stake in Halozyme Therapeutics during the fourth quarter valued at about $60,054,000. Capital World Investors purchased a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $35,773,000. Arrowstreet Capital Limited Partnership grew its position in Halozyme Therapeutics by 141.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock worth $47,470,000 after purchasing an additional 581,475 shares during the last quarter. D. E. Shaw & Co. Inc. increased its stake in Halozyme Therapeutics by 171.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after purchasing an additional 524,802 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Halozyme Therapeutics in the fourth quarter worth $21,838,000. Institutional investors own 97.79% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on HALO. Leerink Partners downgraded Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price on the stock. in a research report on Tuesday, May 13th. Benchmark cut Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Leerink Partnrs cut Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. JPMorgan Chase & Co. raised their price objective on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Finally, HC Wainwright restated a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, May 29th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, Halozyme Therapeutics has a consensus rating of "Hold" and an average price target of $61.90.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 503 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total value of $32,217.15. Following the sale, the director now owns 33,108 shares in the company, valued at $2,120,567.40. This trade represents a 1.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Stock Performance

HALO stock traded up $0.69 during trading on Thursday, hitting $54.54. 1,131,852 shares of the company traded hands, compared to its average volume of 1,633,873. The stock's 50-day simple moving average is $57.41 and its 200 day simple moving average is $56.03. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The company has a market cap of $6.72 billion, a PE ratio of 15.90, a P/E/G ratio of 0.42 and a beta of 1.19. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.13. The company had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Halozyme Therapeutics's quarterly revenue was up 35.2% on a year-over-year basis. During the same period last year, the business earned $0.79 earnings per share. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.